MarketPulse

tolerability

5 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Relay Therapeutics

Relay Therapeutics Advances Breast Cancer Drug Combo Toward Phase 3 Trial

Relay Therapeutics reports positive Phase 2 data for zovegalisib triplet combination in metastatic breast cancer, planning Phase 3 launch in early 2027.
PFERLAYPhase 3 trialzovegalisib
GlobeNewswire Inc.GlobeNewswire Inc.··Sanofi

Sanofi's Nuvaxovid Outperforms Moderna mRNA Vaccine in Tolerability Study

Sanofi's Nuvaxovid shows 50% fewer severe side effects than Moderna's mRNA vaccine in clinical trial, with patients twice as likely to choose it again.
SNYMRNAclinical trialCOVID-19 vaccine
GlobeNewswire Inc.GlobeNewswire Inc.··Sanofi

Sanofi's Nuvaxovid Shows Superior Safety Profile Against Moderna's mRNA Vaccine

Sanofi's protein-based COVID-19 vaccine demonstrated significantly lower side effects than Moderna's mNEXSPIKE in head-to-head trial of 1,000 adults.
SNYMRNAclinical trialCOVID-19 vaccine
GlobeNewswire Inc.GlobeNewswire Inc.··Zealand Pharma

Zealand Pharma's Petrelintide Shows Promise in Obesity Drug Race

Zealand Pharma reports positive Phase 2 data for petrelintide, achieving 10.7% weight loss versus 1.7% placebo with favorable safety profile.
RHHBYZLDPYobesityweight management
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Starton Advances Subcutaneous Lenalidomide Program With Phase 2a Multiple Myeloma Trial Launch

Starton launches Phase 2a trial for subcutaneous lenalidomide delivery in multiple myeloma, comparing three dose levels against standard oral Revlimid treatment.
BMYCELGrclinical developmentmultiple myeloma